BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nicotinic acetylcholine receptors (nAChRs). It exhibits good CNS-agent-like properties and clinical candidate potential.
BNC375 significantly potentiates the acetylcholine signal without altering rapid receptor desensitization. It has demonstrated efficacy in reversing scopolamine-induced cognitive impairment in mouse models. T
he compound has a plasma half-life of 1.2 hours and shows promising pharmacokinetic properties, including good oral bioavailability.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | BNC-375, BNC 375 |
|---|---|
| IUPAC Name | 4-((1R, 3R)-3-(((5-chloro-2-methoxyphenyl)amino)methyl)-2, 2-dimethylcyclopropyl)benzenesulfonamide |
| CAS | 1557240-80-8 |
| Molecular Weight | 394.914 |
| Molecular Formula | C19H23ClN2O3S |
| SMILES | O=S(C1=CC=C([C@H]2C(C)(C)[C@@H]2CNC3=CC(Cl)=CC=C3OC)C=C1)(N)=O |